United Therapeutics Stock Hit by Goldman Sachs Sell Rating

United Therapeutics' stock has been hit by a sell rating from Goldman Sachs, which could reshape investors' long-term investment narrative. The company is progressing a broad pulmonary pipeline, including nebulized Tyvaso for idiopathic pulmonary fibrosis and once-daily oral ralinepag.

It's continuing share repurchases under a $2 billion authorization and advancing xenotransplantation programs such as the xenokidney registration trial targeting potential commercial availability by 2030. This breadth of pipeline and organ manufacturing ambition concentrates capital and execution risk in a few complex cardiopulmonary and transplant platforms.

The company's long-term investment narrative could be reshaped by Goldman Sachs' recent sell initiation, particularly if investors reassess their comfort level with the concentrated R&D load despite near-term rating noise. United Therapeutics' current analyst storyline points to $4.5 billion in revenue and $1.8 billion in earnings by 2029.